2025
Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice
Sharma L, Singh R, Ngeow C, van der Geest R, Duray A, Tolman N, McVerry B, Dela Cruz C, Alcorn J, Bain W, Robinson K. Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice. Physiological Reports 2025, 13: e70232. PMID: 39921246, PMCID: PMC11805821, DOI: 10.14814/phy2.70232.Peer-Reviewed Original ResearchConceptsMurine model of influenzaIL-6 deletionMRSA pneumoniaModel of influenzaInflammatory cell recruitmentIL-6Interferon-stimulated genesMurine modelCell recruitmentJAK inhibitionElevated levels of IL-6Tissue injuryLevels of IL-6IL-6 deficiencyJAK inhibitor baricitinibSuppression of cytokinesLimit tissue injuryLung tissue injurySecondary bacterial infectionInfluenza infectionJAK/STAT signaling pathwayBaricitinib treatmentInhibitory therapyClinical efficacyBacterial burden
2023
2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
VanScoy B, Jones S, Conde H, Vincent C, Bhavnani S, Rubino C, Aronin S, Puttagunta S, Ambrose P. 2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2185. PMCID: PMC10678615, DOI: 10.1093/ofid/ofad500.2185.Peer-Reviewed Original ResearchUncomplicated urinary tract infectionsDose-ranging studyVitro infection modelMedical CenterMIC ratioInfection modelNet bacterial stasisUrinary tract infectionPK-PD indexDose fractionation studiesPlasma concentration-time profilesOral drug administrationGrant/research supportOne-compartmentTotal daily exposureConcentration-time profilesDrug-resistant pathogensTract infectionsMIC targetsOral prodrugOrganic anion transport inhibitorBacterial burdenMIC valuesRenal excretionDose selection2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
VanScoy B, Conde H, Vincent C, Bhavnani S, Aronin S, Puttagunta S, Ambrose P. 2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2186. PMCID: PMC10677872, DOI: 10.1093/ofid/ofad500.2186.Peer-Reviewed Original ResearchVitro infection modelUncomplicated urinary tract infectionsDrug-resistant subpopulationsMedical CenterInfection modelUrine concentrationsDrug resistance amplificationMurine thigh modelUrinary tract infectionEscherichia coli clinical isolatesInitial burdenFree drug plasma concentrationSimulated pharmacokinetic profilesFive-day study periodGrant/research supportConcentration-time profilesPO q12hTract infectionsOral prodrugOrganic anion transport inhibitorBacterial burdenControl regimenPharmacodynamic evaluationRenal excretionPlasma concentrations
2022
Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis
Kwon H, Yu K, Cahill S, Alder K, Dussik C, Kim S, Sharma L, Back J, Oh I, Lee F. Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis. EMBO Molecular Medicine 2022, 14: emmm202115284. PMID: 36354099, PMCID: PMC9728052, DOI: 10.15252/emmm.202115284.Peer-Reviewed Original ResearchConceptsDrug dimethyl fumarateSeptic arthritisIntracellular MRSABacterial joint infectionSoft tissue infectionsAnti-inflammatory effectsInfection-associated inflammationNovel therapeutic paradigmContext of infectionConventional antibiotic treatmentHost cellsAdjuvant administrationSurgical treatmentTissue infectionsClinical symptomsInflammatory machineryJoint infectionBacterial burdenAntibiotic treatmentCell inflammationHost inflammationArthritisInflammationIntraarticular inflammationTherapeutic paradigmHuman neutrophil development and functionality are enabled in a humanized mouse model
Zheng Y, Sefik E, Astle J, Karatepe K, Öz HH, Solis AG, Jackson R, Luo HR, Bruscia EM, Halene S, Shan L, Flavell RA. Human neutrophil development and functionality are enabled in a humanized mouse model. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2121077119. PMID: 36269862, PMCID: PMC9618085, DOI: 10.1073/pnas.2121077119.Peer-Reviewed Original ResearchConceptsHumanized mouse modelMouse modelHuman immune systemHuman neutrophilsImmune systemFunctional human immune systemGranulocyte colony-stimulating factorUnique mouse modelColony-stimulating factorHuman G-CSFMISTRG miceG-CSF receptor geneBacterial burdenInfectious challengeG-CSFNeutrophilsMiceNeutrophil developmentReceptor geneDiseaseTreating ‘Septic’ With Enhanced Antibiotics and ‘Arthritis’ by Mitigation of Excessive Inflammation
Kwon HK, Dussik CM, Kim SH, Kyriakides TR, Oh I, Lee FY. Treating ‘Septic’ With Enhanced Antibiotics and ‘Arthritis’ by Mitigation of Excessive Inflammation. Frontiers In Cellular And Infection Microbiology 2022, 12: 897291. PMID: 35755835, PMCID: PMC9218192, DOI: 10.3389/fcimb.2022.897291.Peer-Reviewed Original ResearchConceptsSeptic arthritisBacterial burdenAntibiotic treatmentMurine modelTherapeutic goalsConcurrent antimicrobial therapyDistinct therapeutic goalsGeneration of inflammationMRSA septic arthritisSeptic knee arthritisInflammatory joint conditionsArticular cartilageMitigation of inflammationPost-antibiotic treatmentNovel therapeutic strategiesSeptic arthritis modelArticular cartilage damageEx vivo modelArticular cartilage integrityInflammatory arthritisInhibitors of ERKInflammatory profileMRSA infectionSynovial tissueExcessive inflammationA mixed-methods evaluation on the efficacy and perceptions of needleless connector disinfectants
Roberts SC, Hendrix CA, Edwards LM, Feinn RS, Martinello RA, Murray TS. A mixed-methods evaluation on the efficacy and perceptions of needleless connector disinfectants. Infection Control And Hospital Epidemiology 2022, 44: 230-233. PMID: 35387702, PMCID: PMC9929708, DOI: 10.1017/ice.2022.72.Peer-Reviewed Original ResearchConceptsNeedleless connectorsMixed-methods evaluationNursing staffOverall bacterial burdenBloodstream infection preventionAcademic tertiary hospitalIsopropyl alcohol wipesSterile water controlTertiary hospitalNursing assessmentBacterial burdenInfection preventionImproved complianceStaff complianceChlorhexidine gluconateScrub timeConvenience sampleAlcohol wipesStaphylococcus epidermidisEfficacyProduct efficacyDry timeWipesDisinfection practicesCompliance
2020
Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, Hung CF, Karakousis PC. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Frontiers In Immunology 2020, 11: 680. PMID: 32411131, PMCID: PMC7198710, DOI: 10.3389/fimmu.2020.00680.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, BacterialAntitubercular AgentsBacterial ProteinsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineChronic DiseaseDrug Resistance, BacterialFemaleGuanosine PentaphosphateGuinea PigsHydrolasesIsoniazidLigasesMacrophagesMiceMice, Inbred C57BLMycobacterium tuberculosisTreatment OutcomeTuberculosisTuberculosis VaccinesVaccinationVaccines, DNAConceptsTherapeutic vaccinationDNA vaccineT cellsC57BL/6 miceMtb persistersGuinea pigsAntigenic environmentFirst-line anti-TB drugsChronic TB infectionDrug-susceptible tuberculosisLung bacterial burdenAnti-TB drugsSpleens of miceHartley guinea pigsActivity of isoniazidAntitubercular treatmentReactive CD4Reactive CD8TB chemotherapyTB infectionTB treatmentCurrent regimenDaily dosesBacterial burdenIsoniazid treatmentOxygen nipple and nut (Christmas tree) adaptor contamination rates and decontamination with disinfecting wipes
Colandrea NA, Cleary ML, Peaper DR, Sullivan LK, Martinello RA, Murray TS. Oxygen nipple and nut (Christmas tree) adaptor contamination rates and decontamination with disinfecting wipes. Infection Control And Hospital Epidemiology 2020, 41: 396-399. PMID: 31983357, DOI: 10.1017/ice.2020.9.Peer-Reviewed Original Research
2016
Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease
Pillai PS, Molony RD, Martinod K, Dong H, Pang IK, Tal MC, Solis AG, Bielecki P, Mohanty S, Trentalange M, Homer RJ, Flavell RA, Wagner DD, Montgomery RR, Shaw AC, Staeheli P, Iwasaki A. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science 2016, 352: 463-466. PMID: 27102485, PMCID: PMC5465864, DOI: 10.1126/science.aaf3926.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAnimalsBacterial InfectionsCaspase 1CaspasesCaspases, InitiatorFemaleHumansImmunity, InnateInfluenza A virusInfluenza, HumanInterferon-betaMaleMembrane GlycoproteinsMiceMonocytesMyxovirus Resistance ProteinsNeutrophilsOrthomyxoviridae InfectionsRespiratory Tract InfectionsToll-Like Receptor 7Viral LoadYoung AdultConceptsBacterial burdenAntiviral resistanceNeutrophil-dependent tissue damageMyD88-dependent signalingAntiviral interferon productionCaspase-1/11IAV diseaseViral loadInfluenza diseaseOlder humansTissue damageInterferon productionInflammasome responseOlder adultsTLR7Vivo consequencesDiseaseMiceIAVBurdenMx geneHumansMonocytesMortalityInfluenzaThe 11S Proteasome Subunit PSME3 Is a Positive Feedforward Regulator of NF-κB and Important for Host Defense against Bacterial Pathogens
Sun J, Luan Y, Xiang D, Tan X, Chen H, Deng Q, Zhang J, Chen M, Huang H, Wang W, Niu T, Li W, Peng H, Li S, Li L, Tang W, Li X, Wu D, Wang P. The 11S Proteasome Subunit PSME3 Is a Positive Feedforward Regulator of NF-κB and Important for Host Defense against Bacterial Pathogens. Cell Reports 2016, 14: 737-749. PMID: 26776519, PMCID: PMC4740229, DOI: 10.1016/j.celrep.2015.12.069.Peer-Reviewed Original ResearchConceptsToll-like receptorsNF-κB pathwayBacterial infectionsHost defenseNF-κB regulationNF-κBNF-κB transcriptional activityNF-κB-mediated transcriptionBacterial burdenImmune responseTranscriptional activityInnate immunityInfectionHematopoietic cellsBacterial pathogensFeedforward mechanismPSME3MacrophagesHost tissuesNegative regulatorPathwayImmunityReceptors
2001
Coinfection with Borrelia burgdorferi and the Agent of Human Granulocytic Ehrlichiosis Alters Murine Immune Responses, Pathogen Burden, and Severity of Lyme Arthritis
Thomas V, Anguita J, Barthold S, Fikrig E. Coinfection with Borrelia burgdorferi and the Agent of Human Granulocytic Ehrlichiosis Alters Murine Immune Responses, Pathogen Burden, and Severity of Lyme Arthritis. Infection And Immunity 2001, 69: 3359-3371. PMID: 11292759, PMCID: PMC98295, DOI: 10.1128/iai.69.5.3359-3371.2001.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisLyme arthritisDual infectionBacterial burdenImmune responseTumor necrosis factor-alpha levelsB. burgdorferiElevated IL-6 levelsNecrosis factor-alpha levelsGranulocytic ehrlichiosisIL-6 levelsAgent of HGEMurine immune responseBorrelia burgdorferiTick-borne illnessMurine Lyme arthritisSevere Lyme arthritisCoinfection of miceIFN-gamma receptor expressionInfected miceInterleukin-12Receptor expressionGamma interferonArthritisPathogen burden
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply